Ovarian Cancer (OC) is the 5th most common tumor in women and also the most widespread gynecological cancer.
The rates of ovarian cancer are high in some major developed regions, being specifically high in the Northern Europe region, according to Cancer Research, UK, 2008. Major advancements in the treatment of ovarian cancer have been done in the last few years through the introduction of platinum-based compounds, as well as improvements in surgical procedures.
Browse Full Research Report With TOC on @ http://www.radiantinsights.com/research/ovarian-cancer-therapeutics-in-major-developed-markets-to-2020-late-stage-pipeline-focuses-on-improved-progression-free-surival-and-targeted-therapies
The global market for ovarian cancer therapeutics is dominated by the usage of generics-predominately carboplatin & paclitaxel that are used together in the treatment of platinum-sensitive ailments (both first line as well as recurrent). The global ovarian cancer therapeutics market is expected to grow at a CAGR of 3.3% to USD 1.8 billion during the forecast period (from 2014 to 2020).
Early treatments with platinum-based therapy are generally effective, with almost 60 to 70% of cases entering remission. However, on the other hand, even with an extended Progression Free Survival (PFS) of one year, almost all cases relapse; and after some successive remission & relapse periods, they either die or develop platinum-resistant ailment, for which the diagnosis is poor. There is an obvious gap in the global market for maintenance therapies to expand the early huge rates of remission, as well as a gap for extra efficient therapy choices in refractory or platinum-resistant patients.
See More Reports of This Category by Radiant Insights: www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
The existing developmental pipeline notices such gaps in the global market. However, effectiveness with late-stage therapeutics has been poor, at best representing nominal developments in PFS. In the Europe region, both the drugs i.e., Yondelis and Avastin are approved based on the improvements in PFS. Thus, it is expected that the pipeline drugs that exhibited the major developments in PFS, such as Vynfinit, olaparib, & trebananib, will get approved in the region. But, on the other hand, the lack of great improvements in medical benefits with these drugs, as well as their estimated higher prices are said to limit their demand or sales.
In the US, the observed PFS improvements with Avastin & Yondelis, in the absence of other medical benefits with either drug, caused disapprovals of these drugs. As a result, the market is projected to be mainly driven by inflation & an increase in the occurrences of pancreatic cancer.
Explore Other Reports By Radiant Insights,Inc at
- Industrial Rubber Products Industry –
- Consumer Software Industry –
- Asphalt Industry –
About Radiant Insight
Radiant Insights is a market research and consulting company offering syndicated research studies, customized reports, and consulting services. Our market research studies are designed to facilitate strategic decision making, on the basis of extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Using a patented and robust research methodology, we publish exhaustive research reports covering a host of industries such as Technology, Chemicals, Materials, and Energy. Radiant Insights has a strong base of analysts, consultants and domain experts, with global experience helping us deliver excellence in all research projects we undertake.
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
Country: United States